Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. - Margolis, David A.; Gonzalez-Garcia, Juan; Stellbrink, Hans-Jürgen; Eron, Joseph J.; Yazdanpanah, Yazdan; Podzamczer, Daniel; Lutz, Thomas; Angel, Jonathan B.; Richmond, Gary J.; Clotet, Bonaventura; Gutierrez, Felix; Sloan, Louis; et al. (Lancet, 2017)